Insmed Incorporated (LON:0JAV)

London flag London · Delayed Price · Currency is GBP · Price in USD
100.48
-1.52 (-1.49%)
At close: Jun 27, 2025
47.98%
Market Cap 13.78B
Revenue (ttm) 294.91M
Net Income (ttm) -784.26M
Shares Out n/a
EPS (ttm) -4.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 663
Average Volume 1,799
Open 101.67
Previous Close 102.00
Day's Range 100.48 - 102.11
52-Week Range 61.28 - 106.50
Beta 0.79
RSI 69.07
Earnings Date Aug 7, 2025

About Insmed

Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 c... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1988
Employees 1,271
Stock Exchange London Stock Exchange
Ticker Symbol 0JAV
Full Company Profile

Financial Performance

In 2024, Insmed's revenue was $363.71 million, an increase of 19.17% compared to the previous year's $305.21 million. Losses were -$913.77 million, 21.9% more than in 2023.

Financial numbers in USD Financial Statements

News

What Does the Market Think About Insmed?

Insmed's (NYSE: INSM) short percent of float has risen 5.99% since its last report. The company recently reported that it has 17.46 million shares sold short , which is 10.8% of all regular shares th...

11 days ago - Benzinga

Is Insmed Stock Overvalued After The 45% Jump?

Insmed Inc (NASDAQ: INSM) was nothing short of a powerhouse last month, soaring 45%, while the S&P 500 index rose 3% in the same timeframe. What's driving this surge?

14 days ago - Forbes

Insmed Announces Pricing of $750 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...

18 days ago - PRNewsWire

$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today

Insmed (NASDAQ: INSM) has outperformed the market over the past 10 years by 4.43% on an annualized basis producing an average annual return of 15.51%. Currently, Insmed has a market capitalization of...

19 days ago - Benzinga

Insmed Announces Proposed $650 Million Public Offering of Common Stock

BRIDGEWATER, N.J. , June 11, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor...

19 days ago - PRNewsWire

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Insmed Incorporated (NASDAQ: INSM) on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary ar...

19 days ago - Benzinga

Insmed's Pulmonary Hypertension Drug Data Exceeded Even Bullish Outlook, Analysts Boost Price Forecast

Insmed Incorporated INSM on Tuesday released topline results from its Phase 2b study of treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hype...

19 days ago - Benzinga

Datadog To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Needham r...

19 days ago - Benzinga

Insmed CEO Will Lewis on stock surge after positive trial results

Will Lewis, Insmed Chair & CEO, joins 'Fast Money' to talk its recent trial results for Pulmonary Arterial Hypertension therapy, the stock reaction, and more.

20 days ago - CNBC Television

Insmed CEO Will Lewis on stock surge after positive trial results

Will Lewis, Insmed Chair & CEO, joins 'Fast Money' to talk its recent trial results for Pulmonary Arterial Hypertension therapy, the stock reaction, and more.

20 days ago - CNBC

3 Stocks With The 'Insider Advantage'

There’s a well-worn line in value investing circles that says, “I want to invest with people who eat their own cooking.” In other words, you want the people running the company to have a meaningful ch...

20 days ago - Benzinga

Insmed Stock Soars on Pulmonary Arterial Hypertension Drug Trial Results

Shares of Insmed jumped Tuesday after the biopharmaceutical firm reported positive results from a Phase 2 trial for its treatment of pulmonary arterial hypertension.

20 days ago - Investopedia

Dow Gains 50 Points; US Small Business Optimism Index Rises In May

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 50 points n Tuesday. The Dow traded up 0.13% to 42,817.81 while the NASDAQ gained 0.22% to 19,634.48. The S...

20 days ago - Benzinga

Caseys Enjoys 'Good Quarter,' Analyst Praises Steady Fuel Volumes

Stephens analyst Pooran Sharma reiterated the Overweight rating on Caseys General Stores, Inc. (NASDAQ: CASY), with a price forecast of $490. On June 9, the company reported fourth-quarter financial ...

20 days ago - Benzinga

Stocks making the biggest moves midday: Topgolf Callaway, Insmed, J.M. Smucker, SolarEdge & more

These are the stocks posting the largest moves midday.

20 days ago - CNBC

Insmed's blood pressure drug meets main goal in mid-stage trial

Insmed said on Tuesday that its experimental blood pressure drug met the main goals in a mid-stage study.

20 days ago - Reuters

Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

–The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p

20 days ago - PRNewsWire

Mizuho's Jared Holz details potential biotech, pharma acquisitions

Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries.

26 days ago - CNBC Television

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J. , June 4, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

26 days ago - PRNewsWire

Insmed To Present at the 2025 Goldman Sachs Annual Global Healthcare Conference

BRIDGEWATER, N.J. , May 28, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform...

4 weeks ago - PRNewsWire